Author Affiliations: The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire (Dr Woloshin); and VA Outcomes Group, White River Junction, Vermont (Dr Schwartz).
It is unlikely that direct-to-consumer ads are going to be banned any time soon. This underscores the need to provide physicians and patients with independent, balanced information about the benefits, harms, and uncertainties of Food and Drug Administration (FDA)-approved prescription drugs. A number of groups have undertaken such efforts including academics,1 policy groups,2 and consumer organizations.3 We have proposed that the FDA itself produce standardized 1-page summaries, called drug facts boxes, to provide the necessary information. On the basis of a body of evidence, including national randomized trials demonstrating that drug boxes improve patient decision making,4 the FDA's Risk Communication Advisory Committee unanimously recommended that the FDA adopt the Drug Facts Box as the standard format for all communications. Unfortunately, the FDA has made no steps toward implementing this recommendation.5 The rapid uptake of many newly approved drugs—often with minimal benefits over placebo and uncertain safety records—suggests physicians may also overinterpret the meaning of FDA approval in terms of drug efficacy and safety. Physicians clearly need better drug information also.
Schwartz LM, Woloshin S. Conservative Prescribing and the Importance of Psychotherapy—Reply. Arch Intern Med. 2012;172(3):294–295. doi:10.1001/archinternmed.2011.1405
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: